Lite Strategy Q4 EPS $(0.38) Up From $(0.40) YoY
Lite Strategy Inc LITS
$1.38
▲ +1.10%
(+$0.02)
Open
$1.35
Prev Close
$1.36
Day Range
$1.34 – $1.41
52W Range
$0.69 – $2.97
Market Cap
$46.78M
Beta
0.03
EPS (TTM)
$-1.74
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2003-12-18 |
| Shares Out. | 34,030,000 |
| Website | litestrategy.com/ ↗ |
| Phone | 13026587581 |
| Employees | 4 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$13.0M |
| Free Cash Flow | -$9.1M |
| Total Assets | $42.7M |
| Total Liabilities | $1.1M |
| Equity | $41.6M |
About Lite Strategy Inc
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
Lite Strategy Inc is a publicly traded company under the ticker symbol LITS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2025-11-01)